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Editorial on the Research Topic
Immuno-Metabolism in Tumor Microenvironment
From Hanahan and Weinberg’s original description of six hallmarks of cancer (self-sufficiency in 
growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis) (1), it took only 11 years to add 
in 2011, based on an increasing body of research, two “emerging hallmarks of cancer”: deregulating 
cellular energetics and avoiding immune destruction (2). Hanahan and Weinberg also pointed out 
that, besides cancer cells, tumors contain a repertoire of recruited normal cells that contribute to 
create the “tumor microenvironment” (2). Deregulating cellular energetics is perhaps most com-
monly known as metabolic reprogramming, a process that can take place in tumor cells (3), as well 
as in tumor-infiltrating immune cells (4). The interplay between specific metabolic pathways, in 
the context of cell maturation, activation, differentiation, and effector functions of immune cells, is 
currently referred to as immuno-metabolism (5). Metabolic reprogramming and avoiding immune 
destruction are closely interrelated, since metabolic intermediates from tumor cells may suppress 
the immune response (4).
The research topic “Immuno-metabolism in tumor microenvironment,” here presented, covers 
several aspects of tumor and immune cell metabolism, as well as the cell–cell interplay within the 
tumor, at the metabolic level. In addition, some metabolic-oriented cancer therapies are reviewed 
(Molon et al.; Ohta; Romero-Garcia et al.; Salazar-Ramiro et al.; Zhang and Ertl).
tUMor StrUCtUrE
Tumors comprised an intricate network of tumor cells, fibroblasts, endothelial cells, immune 
inflammatory cells, adipocytes, extracellular matrix molecules, and soluble factors. All these 
elements contribute to form a structure that favors the development of gradients of oxygen tension 
and nutrients availability. According to Zhang and Ertl, it is estimated that 50–60% of solid tumors 
possesses unevenly distributed areas of hypoxia with consequences for individual cell metabolism, 
functionality and survival and, finally, for tumor outcome.
tUMor CEll MEtaBoliSM
Tumor cells undergo metabolic reprogramming, which allows for their survival; and it is stromal 
cells (immune cells, fibroblasts, endothelial cells, etc.) that have to endure the consequences of tumor 
metabolic reprogramming. Otto Warburg initially described that tumor cells are highly glycolytic, 
even in the presence of oxygen, and produce large amounts of lactate, up to 40 times as much as that 
of normal cells. As Romero-Garcia et al. pointed out, lactate is not just a by-product of glycolysis; 
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instead, it is an active metabolite that promotes angiogenesis 
and induces profound effects on both tumor cells (metabolic 
symbiosis) and immune system cells (immune suppression). 
Besides lactate, other metabolites are released within the tumor 
microenvironment; importantly, adenosine, which accumulates 
at the tumor extracellular milieu, under hypoxic conditions. 
Akio Ohta focuses his review on the effects of this metabolite on 
tumor and immune cells. Adenosine may support tumor progres-
sion directly, whereas it suppresses pro-inflammatory activities. 
Blocking of the hypoxia–adenosine pathway is discussed as a 
possible target for cancer immunotherapy (Ohta). Interestingly, 
from these two reviews, it emerges that lactate and adenosine 
have similar effects on tumors (tumor progression and immune 
suppression), albeit different mechanisms.
As a result of the increased metabolic activity in the tumor cells, 
reactive oxygen species are released into the microenvironment, 
which might favor inflammation and progression of cancer (6). 
Salazar-Ramiro et al. discuss the imbalance in the redox status 
in glioblastoma multiforme, and the effects that a highly oxidant 
environment has on genomic instability, gliomagenesis, and 
tumor progression and, finally, how the redox balance might be 
an attractive target for therapy against glioblastoma multiforme.
MEtaBoliSM oF tUMor-iNFiltratiNG 
iMMUNE CEllS
Tumor-infiltrating lymphocytes are challenged with a hostile 
environment, notably hypoxia and nutrients scarceness, not to 
mention high amounts of lactate, adenosine, and anti-inflamma-
tory cytokines. Tumor areas with low oxygen tension arise from 
structural and functional abnormalities of the tumor microvascu-
lature and a high proliferation rate of tumor cells. Thus, immune 
cells are frequently infiltrating hypoxic areas, which might favor 
the inhibition of immune cell functions. Therapies, such as adop-
tive T cell transfer or immunomodulatory antibodies should take 
into account that activated effector T cells will be under hypoxic 
conditions, which might explain why these therapies have not 
been as successful as expected. Zhang and Ertl review how hypoxia 
favors the expression of co-inhibitory molecules, and inhibits cell 
proliferation and production of granzymes and perforin by CD8+ 
T cells. The effect of glucose deprivation on T cell activation is 
also reviewed (Zhang and Ertl). Amino acid metabolism repre-
sents an important process that might favor tumor progression 
and limit immune responses. Molon et al. review the effects of 
tumor microenvironment in T cell metabolism and the metabolic 
adaptations of T cells within the tumor, examining some immune 
checkpoints, such as programmed death receptor-1 (PD-1) and 
cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), and 
signaling pathways, such as PI3K/Akt/mTOR, and their role in 
energetic adaptations of both cancer and immune cells.
CoNClUdiNG rEMarKS
What happens to individual cells within a solid tumor is reminis-
cent of the concept created by Spanish philosopher José Ortega 
y Gasset: “I am I and my circumstance; and, if I do not save it, I 
do not save myself.” In this case, the life of an organism (tissue 
or cells) is formed by the organism itself and by its medium; if 
the medium changes the organism changes and vice  versa. In 
the original quote, there is not determinism at all, since human 
beings have logos.
If tumor cells are within a hypoxic area, they produce adeno-
sine and lactate, among other metabolites. If in an oxygenated 
area, tumor cells, that are suited to metabolize glucose by glyco-
lysis, rely on lactate instead, sparing glucose for hypoxic tumor 
cells. Cytotoxic T lymphocytes and other tumor-infiltrating cells 
live starved and asphyxiated and yet they fight tumor cells, while 
their surrounding medium provide immunosuppressive signals 
that later affect their function.
The five papers that comprise this topic suggest that, perhaps, 
for effective anti-cancer therapeutics, researches have to consider 
not only the cells (tumor and immune cells) but the cells and their 
circumstance, as a whole.
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